Improved delivery of angiogenesis inhibitors from PLGA: poloxamer blend micro- and nanoparticles

Ivana D'Angelo, Yolanda Parajó, Anikó Horvth, G. Kéri, Maria Immacolata La Rotonda, María José Alonso

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Clinical studies have demonstrated the efficacy of new strategies in cancer therapy, such as chemotherapy and radiotherapy, associated to the administration of tumour vascularization inhibitors. A critical limitation for the clinical application of angiogenesis inhibitors relies in their instability in biological environment and high-dose requirements. This work has attempted to overcome this limitation by designing an adequate delivery vehicle consisting of PLGA:poloxamer blend micro- and nanoparticles. The potential of this delivery system was investigated for a new synthetic angiogenesis inhibitor named polyaminoacid JS-2892b. PLGA:poloxamer (ratio 10 : 1) blend microparticles were prepared by the oil-in-oil emulsion technique, while PLGA:poloxamer (ratio 1 : 1) blend nanoparticles were obtained by a modified solvent diffusion technique. The results showed that, by adjusting the formulation conditions, it was possible to efficiently encapsulate the polyaminoacid JS-2892b within PLGA:poloxamer micro- (particle size of 20 μm and encapsulation efficiency higher than 90%) and nanoparticles (particle size of less than 280 nm and encapsulation efficiency of 52%). In addition, the delivery of the polyaminoacid JS-2892b from the particles could be controlled, without altering its stability, for extended periods of time (from a few days to over a month). The release of the encapsulated compound was significantly affected by the particle size and the way the drug is dispersed into the polymeric matrix. Therefore, this study provides information about the formulation conditions and potential of biodegradable particles for the controlled release of polyaminoacid JS-2892b.

Original languageEnglish
Pages (from-to)57-66
Number of pages10
JournalJournal of Microencapsulation
Volume27
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Poloxamer
angiogenesis
Angiogenesis Inhibitors
microparticles
Nanoparticles
inhibitors
delivery
Particle size
Particle Size
Encapsulation
nanoparticles
Oils
Chemotherapy
Radiotherapy
oils
Emulsions
Tumors
formulations
chemotherapy
Neoplasms

Keywords

  • Angiogenesis inhibitors
  • Microparticles
  • Nanoparticles
  • PLGA
  • Poloxamer

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Colloid and Surface Chemistry
  • Physical and Theoretical Chemistry
  • Bioengineering
  • Organic Chemistry
  • Medicine(all)

Cite this

Improved delivery of angiogenesis inhibitors from PLGA : poloxamer blend micro- and nanoparticles. / D'Angelo, Ivana; Parajó, Yolanda; Horvth, Anikó; Kéri, G.; La Rotonda, Maria Immacolata; Alonso, María José.

In: Journal of Microencapsulation, Vol. 27, No. 1, 2010, p. 57-66.

Research output: Contribution to journalArticle

D'Angelo, Ivana ; Parajó, Yolanda ; Horvth, Anikó ; Kéri, G. ; La Rotonda, Maria Immacolata ; Alonso, María José. / Improved delivery of angiogenesis inhibitors from PLGA : poloxamer blend micro- and nanoparticles. In: Journal of Microencapsulation. 2010 ; Vol. 27, No. 1. pp. 57-66.
@article{140944e09082413a8c6d8f596d4b5e73,
title = "Improved delivery of angiogenesis inhibitors from PLGA: poloxamer blend micro- and nanoparticles",
abstract = "Clinical studies have demonstrated the efficacy of new strategies in cancer therapy, such as chemotherapy and radiotherapy, associated to the administration of tumour vascularization inhibitors. A critical limitation for the clinical application of angiogenesis inhibitors relies in their instability in biological environment and high-dose requirements. This work has attempted to overcome this limitation by designing an adequate delivery vehicle consisting of PLGA:poloxamer blend micro- and nanoparticles. The potential of this delivery system was investigated for a new synthetic angiogenesis inhibitor named polyaminoacid JS-2892b. PLGA:poloxamer (ratio 10 : 1) blend microparticles were prepared by the oil-in-oil emulsion technique, while PLGA:poloxamer (ratio 1 : 1) blend nanoparticles were obtained by a modified solvent diffusion technique. The results showed that, by adjusting the formulation conditions, it was possible to efficiently encapsulate the polyaminoacid JS-2892b within PLGA:poloxamer micro- (particle size of 20 μm and encapsulation efficiency higher than 90{\%}) and nanoparticles (particle size of less than 280 nm and encapsulation efficiency of 52{\%}). In addition, the delivery of the polyaminoacid JS-2892b from the particles could be controlled, without altering its stability, for extended periods of time (from a few days to over a month). The release of the encapsulated compound was significantly affected by the particle size and the way the drug is dispersed into the polymeric matrix. Therefore, this study provides information about the formulation conditions and potential of biodegradable particles for the controlled release of polyaminoacid JS-2892b.",
keywords = "Angiogenesis inhibitors, Microparticles, Nanoparticles, PLGA, Poloxamer",
author = "Ivana D'Angelo and Yolanda Paraj{\'o} and Anik{\'o} Horvth and G. K{\'e}ri and {La Rotonda}, {Maria Immacolata} and Alonso, {Mar{\'i}a Jos{\'e}}",
year = "2010",
doi = "10.3109/02652040902954729",
language = "English",
volume = "27",
pages = "57--66",
journal = "Journal of Microencapsulation",
issn = "0265-2048",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Improved delivery of angiogenesis inhibitors from PLGA

T2 - poloxamer blend micro- and nanoparticles

AU - D'Angelo, Ivana

AU - Parajó, Yolanda

AU - Horvth, Anikó

AU - Kéri, G.

AU - La Rotonda, Maria Immacolata

AU - Alonso, María José

PY - 2010

Y1 - 2010

N2 - Clinical studies have demonstrated the efficacy of new strategies in cancer therapy, such as chemotherapy and radiotherapy, associated to the administration of tumour vascularization inhibitors. A critical limitation for the clinical application of angiogenesis inhibitors relies in their instability in biological environment and high-dose requirements. This work has attempted to overcome this limitation by designing an adequate delivery vehicle consisting of PLGA:poloxamer blend micro- and nanoparticles. The potential of this delivery system was investigated for a new synthetic angiogenesis inhibitor named polyaminoacid JS-2892b. PLGA:poloxamer (ratio 10 : 1) blend microparticles were prepared by the oil-in-oil emulsion technique, while PLGA:poloxamer (ratio 1 : 1) blend nanoparticles were obtained by a modified solvent diffusion technique. The results showed that, by adjusting the formulation conditions, it was possible to efficiently encapsulate the polyaminoacid JS-2892b within PLGA:poloxamer micro- (particle size of 20 μm and encapsulation efficiency higher than 90%) and nanoparticles (particle size of less than 280 nm and encapsulation efficiency of 52%). In addition, the delivery of the polyaminoacid JS-2892b from the particles could be controlled, without altering its stability, for extended periods of time (from a few days to over a month). The release of the encapsulated compound was significantly affected by the particle size and the way the drug is dispersed into the polymeric matrix. Therefore, this study provides information about the formulation conditions and potential of biodegradable particles for the controlled release of polyaminoacid JS-2892b.

AB - Clinical studies have demonstrated the efficacy of new strategies in cancer therapy, such as chemotherapy and radiotherapy, associated to the administration of tumour vascularization inhibitors. A critical limitation for the clinical application of angiogenesis inhibitors relies in their instability in biological environment and high-dose requirements. This work has attempted to overcome this limitation by designing an adequate delivery vehicle consisting of PLGA:poloxamer blend micro- and nanoparticles. The potential of this delivery system was investigated for a new synthetic angiogenesis inhibitor named polyaminoacid JS-2892b. PLGA:poloxamer (ratio 10 : 1) blend microparticles were prepared by the oil-in-oil emulsion technique, while PLGA:poloxamer (ratio 1 : 1) blend nanoparticles were obtained by a modified solvent diffusion technique. The results showed that, by adjusting the formulation conditions, it was possible to efficiently encapsulate the polyaminoacid JS-2892b within PLGA:poloxamer micro- (particle size of 20 μm and encapsulation efficiency higher than 90%) and nanoparticles (particle size of less than 280 nm and encapsulation efficiency of 52%). In addition, the delivery of the polyaminoacid JS-2892b from the particles could be controlled, without altering its stability, for extended periods of time (from a few days to over a month). The release of the encapsulated compound was significantly affected by the particle size and the way the drug is dispersed into the polymeric matrix. Therefore, this study provides information about the formulation conditions and potential of biodegradable particles for the controlled release of polyaminoacid JS-2892b.

KW - Angiogenesis inhibitors

KW - Microparticles

KW - Nanoparticles

KW - PLGA

KW - Poloxamer

UR - http://www.scopus.com/inward/record.url?scp=75449107543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449107543&partnerID=8YFLogxK

U2 - 10.3109/02652040902954729

DO - 10.3109/02652040902954729

M3 - Article

C2 - 19545221

AN - SCOPUS:75449107543

VL - 27

SP - 57

EP - 66

JO - Journal of Microencapsulation

JF - Journal of Microencapsulation

SN - 0265-2048

IS - 1

ER -